Literature DB >> 18073394

Systemic inflammation in chronic obstructive pulmonary disease: the role of exacerbations.

Emiel F M Wouters1, Karin H Groenewegen, Mieke A Dentener, Juanita H J Vernooy.   

Abstract

The systemic manifestations of chronic obstructive pulmonary disease (COPD) exacerbations are recognized, but our understanding of their etiology and importance is lacking largely due to the small number of systematic and longitudinal studies. Most of the systemic manifestations are likely the result of inflammatory processes. Serum biomarkers, such as various cytokines, adipokines, C-reactive protein, and coagulation factors, are elevated during exacerbations. Our understanding of the systemic manifestations can be greatly enhanced if we integrate what is known about the basic science of systemic mediators with the translational science of their role in COPD exacerbations. Many overlapping connections and promising avenues of future research come to light with such a viewpoint.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18073394     DOI: 10.1513/pats.200706-071TH

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN: 1546-3222


  37 in total

1.  Systemic inflammatory responses in progressing periodontitis during pregnancy in a baboon model.

Authors:  J L Ebersole; M J Steffen; S C Holt; L Kesavalu; L Chu; D Cappelli
Journal:  Clin Exp Immunol       Date:  2010-12       Impact factor: 4.330

2.  NF-κB activation is required for the transition of pulmonary inflammation to muscle atrophy.

Authors:  Ramon C J Langen; Astrid Haegens; Juanita H J Vernooy; Emiel F M Wouters; Menno P J de Winther; Harald Carlsen; Chad Steele; Steven E Shoelson; Annemie M W J Schols
Journal:  Am J Respir Cell Mol Biol       Date:  2012-04-26       Impact factor: 6.914

3.  Liver microsomal beta-glucuronidase and UDP-glucuronyltransferase.

Authors:  I Schöllhammer; D S Poll; M H Bickel
Journal:  Enzyme       Date:  1975

4.  Chronic obstructive pulmonary disease associated with increased risk of bipolar disorder.

Authors:  Vincent Yi-Fong Su; Li-Yu Hu; Chiu-Mei Yeh; Huey-Ling Chiang; Cheng-Che Shen; Kun-Ta Chou; Tzeng-Ji Chen; Ti Lu; Cheng-Hwai Tzeng; Chia-Jen Liu
Journal:  Chron Respir Dis       Date:  2016-01-01       Impact factor: 2.444

5.  The association of adiponectin with computed tomography phenotypes in chronic obstructive pulmonary disease.

Authors:  Brendan J Carolan; Yu-il Kim; André A Williams; Katerina Kechris; Sharon Lutz; Nichole Reisdorph; Russell P Bowler
Journal:  Am J Respir Crit Care Med       Date:  2013-09-01       Impact factor: 21.405

6.  Reactive oxygen species in peripheral blood and sputum neutrophils during bacterial and nonbacterial acute exacerbation of chronic obstructive pulmonary disease.

Authors:  Mindaugas Vaitkus; Simona Lavinskiene; Diana Barkauskiene; Kristina Bieksiene; Jolanta Jeroch; Raimundas Sakalauskas
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

7.  A pilot study to examine the effects of smoking cessation on serum markers of inflammation in women at risk for cardiovascular disease.

Authors:  Virginia Reichert; Xiangying Xue; Diane Bartscherer; Daniel Jacobsen; Christine Fardellone; Patricia Folan; Nina Kohn; Arunabh Talwar; Christine N Metz
Journal:  Chest       Date:  2009-02-18       Impact factor: 9.410

8.  A new inflammation marker of chronic obstructive pulmonary disease-adiponectin.

Authors:  Juan Xie; Xing-Yi Yang; Jin-Dong Shi; Xing-Qi Deng; Wei Long
Journal:  World J Emerg Med       Date:  2010

9.  Prospective study of lung function and abdominal aortic aneurysm risk: The Atherosclerosis Risk in Communities study.

Authors:  Yasuhiko Kubota; Aaron R Folsom; Kunihiro Matsushita; David Couper; Weihong Tang
Journal:  Atherosclerosis       Date:  2017-10-13       Impact factor: 5.162

10.  An in vitro analysis of the effect of acidosis on coagulation in chronic disease states - a thromboelastograph study.

Authors:  Hayden White; Robert Bird; Kellie Sosnowski; Mark Jones
Journal:  Clin Med (Lond)       Date:  2016-06       Impact factor: 2.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.